The prototypical superantigen MAM is an extracellular T-cell mitogen produced by Mycoplasma arthritidis, an organism which causes chronic proliferative arthritis of rodents. We here describe purification of MAM to homogeneity. Pure MAM exhibits all of the major properties previously described for partially purified MAM, including preference for H-2E molecules in presention to T cells, V. T-cell receptor specificity for T-cell activation, and in vivo inhibition of T-cell functions but enhancement of B-cell activity as mediated by the superantigen bridge. Edman degradation of pure MAM gave a 54-residue partial amino-terminal sequence.
The newly recognized class of superantigens is composed of immunomodulatory protein molecules that have been hypothesized to induce autoimmune diseases (10, 17, 22, 30, 32) . Bacterial exotoxins (4, 24, 29, 30) and cell wall components (34, 35) as well as endogenous mouse tumor provirus and retroviral proteins (1, 23) and rabies virus (27) have been shown to possess superantigenic properties. Mycoplasma arthnitidis, an agent of chronic rodent arthritis, releases a soluble extracellular T-cell mitogen (9) . Subsequent work (reviewed in reference 7) established that the mitogen called MAM activates murine and human lymphocytes and exhibits all of the characteristic properties of superantigens, including presentation to T cells by major histocompatibility complex (MHC) molecules (preferentially, but not restricted to, H-2E) without the need of processing by accessory cells, and recognition of MAM in a non-MHC-restricted manner by specific V,3 chains of the ct/, T-cell receptor for antigen (TCR) (6, 11) .
It was previously found that MAM is a basic, heat-and acid-labile protein with a molecular weight of 15,000 to 30,000 (2, 25) . We hypothesized that the high pI (>9) and hydrophobicity of MAM, and consequent binding of MAM to nucleic acids and other culture macromolecules as well as to surfaces, prevented extensive purification. Considering these properties, we devised a new purification scheme that resulted in homogeneous MAM and the subsequent derivation of its N-terminal sequence.
MATER1ALS AND METHODS
Animals. Animal care was in accordance with institutional guidelines. For use in assays to quantitate mitogen, female CBA/J mice 8 to 12 weeks of age were obtained from Jackson Laboratory (Bar Harbor, Maine).
For comparative studies, the activity of MAM was also tested by using lymphocytes from the following strains of mice that were also obtained from Jackson Laboratory: BALB/c (H-2d, V b), C57BL/10 (H2b, V b) C57BR (H2-2, Va) SWR (H-2q, V 3a), RIIIS (H-2, V1, B10.BR (H-2k, Vg ), and B10.RIII (H-2, V13b).
Quantitative lymphocyte proliferation assay. The assays were performed as previously described (2) . Aliquots of fractions were diluted with complete RPMI 1640 medium (GIBCO, Chagin Falls, Ohio) and sterilized by triple ultrafiltration. Proliferation of CBA/J murine splenocytes by serial dilutions of MAM-containing samples was determined by uptake of [3H]TdR. Ninety-six-well cultures were harvested (Skatron Basic 96 harvester) after 3 days of incubation (37°C in a 5% C02-air mixture) just following a 24-h pulse with 1 ,uCi of [3H]TdR (2 Ci/mmol). Filter mats were counted on a Skatron beta counter. As before, unknown samples were compared with a standard reference preparation of MAM by calculating the dilutions which gave 50% of the optimal [3H]TdR uptake in log-dose-response curves (2) . MAM at 1 U/ml is defined as giving half-maximal proliferation in this standardized assay (2) .
Induction and assay of interleukin-2. (6) , and supematants were collected after 24 to 28 h and assayed for interleukin-2, using reduction of (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide) (MTJ) as a measure of cell growth (31) .
AMEH growth medium. Autoclaved modified Edward-Hayflick (AMEH) medium consisted of 84 g of Bacto PPLO broth without crystal violet (Difco Laboratories, Detroit, Mich.), 62.5 g of Fleischmann's dry baker's yeast, 750 ml of defined equine serum (HyClone, Logan, Utah), and 4,250 ml of Millipore deionized water (Millipore Corp., Bedford, Mass.). After autoclaving at 15 lb/in2 (132°C) for 40 min, the mixture was cooled in an ice bath overnight and was then centrifuged in polycarbonate centrifuge bottles at 11,000 relative centrifugal force (i.e., at 9,000 rpm in a Beckman JA-10 rotor) for 30 min at 40C without braking. Floating residues were discarded; supernatants were decanted through cheesecloth layers, and if the supernatant was not particle free, it was again centrifuged. N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid (HEPES; 1% [wt/vol]; Sigma Chemical Co., St. Louis, Mo.) and 0.5% arginine * HCl (Sigma) were then added. After being adjusted to pH 7.0 with NH40H, the medium was autoclaved in two 4-liter flasks for 15 min with nonabsorbent cotton stoppers. If necessary, further clarification was performed by pressure ultrafiltration on largediameter 0.22-,um-pore-size MF filters (Millipore); alternatively, ultrafiltration supplanted the second autoclaving. The sterile medium was supplemented with 1,000 U of penicillin G (Apotheon, Pinceta, N.J.) per ml.
Culture procedures and turbidimetry. For inocula, 1-ml aliquots of mid-exponential-phase, 37°C cultures of various strains of M. arthritidis in Edward-Hayflick medium (20) or modified Edward-Hayflick medium (2) were frozen at -70°C. For screening strains, cultures in 5 ml of modified EdwardHayflick medium were grown for 7 days at 37°C in very slowly rotated cotton-stoppered tubes.
To produce MAM for purification, M. arthritidis PG6 (ATCC 19611 ) was adapted to grow in AMEH broth by six serial passages, and 5-ml aliquots were stored at -70°C. For inoculation, two vials of M. arthritidis culture were rapidly thawed at .370C, and each was added to 21 of AMEH medium preheated to 37°C. Incubation at 37°C was continued without stirring for 24 h, after which gentle stirring at 25 rpm was maintained on an orbital table with 2-cm-diameter motion. Hourly, starting at 48 h, aliquots were aseptically withdrawn from the flasks and cooled to room temperature, and growth was estimated turbidimetrically from A600 versus an absorbance reference of sterile growth medium. Static or diminishing turbidity, usually with maximum A600 of -0.2/cm at about 52 h in both flasks, indicated the transition from growth maximum to a lytic phase, whereupon the two cultures were combined and immediately subjected to purification. The whole warm senescent culture was subjected to (NH4)2SO4 (Schwarz-Mann ultrapure) fractionation as described by Green and Hughes (18) . The pellet resulting from the 50 to 80% fraction was dissolved in 60 ml of H20, and insoluble residue was removed by centrifugation. The clarified extract was subjected to gel filtration chromatography with eluent buffer 2 at 40 ml/h on a 2-liter column (diameter/height = 1:5 to 1:10) of medium-grade Sephadex G-50 (Pharmacia-LKB, Piscataway, N.J.) that had previously been equilibrated with buffer 1. One fraction of 200 ml was collected according to elution volumes previously determined for 30-kDa molecular size standard carbonic anhydrase (Sigma). Conductivity and pH of the collected fraction were decreased to the values of buffer 2 by dialysis or by repeated dilution with buffer 2 and centrifugal concentration and ultrafiltration in Centriprep-10 or -30 tubes (Amicon, Danvers, Mass.). The material was then adsorbed onto a 30-ml column (diameter/length = 1:5 to 1:10) of Fast Flow Sepharose-S cation-exchange resin (Pharmacia-LKB) that had been equilibrated with buffer 2. After washing, the column was then subjected to frontal elution with buffer 3. The eluted 280-nm-absorbing peak was equilibrated with buffer 2 as before.
A second cation exchange was performed at 1 ml/min by adsorbing the adjusted fraction onto an HR 5/10 fast protein liquid chromatography (FPLC) column of 1 ml of Mono S resin (Pharmacia-LKB) also preequilibrated with buffer 2. After unabsorbed proteins were washed away, the column was eluted with a 20-ml linear gradient to 40% (vol/vol) buffer 3, with use of a flow cuvette for continuous monitoring at A280, and 0.5-ml fractions were collected.
The final step consisted of hydrophobic interaction chromatography using an HR 5/10 FPLC column containing 1 Purification of MAM. We used the quantitative mitogenicity assay (2) to separately optimize each step of the present procedure, such that elution volumes and absorbance profiles could be used directly for rapid selection of active fractions. Since the yield of MAM from fractionation with (NH4)2SO4 was indifferent to the presence of cells, we added (NH4)2SO4 to 50% saturation directly to the warm senescent culture and thus eliminated cellular debris with the first (NH4)2SO4 precipitate. Precipitate from 80% saturated (NH4)2SO4 mixture was effectively back extracted with 1 M (NH4)2S04, which was calculated to give dissolved MAM in a volume appropriate for the next step of gel filtration chromatography. Sephadex G-50 used for the latter also contained 1 M (NH4)2SO4, giving an ionic strength six times that of 0.5 M buffer A that was previously used (2) for gel filtration on the much slower Sephacryl S-200 Superfine resin (Pharmacia-LKB). Collection of one active fraction (not shown) from G-50 depended upon standardization of the chromatography using a 30-kDa standard protein.
These modifications to our previous procedure were required before impure MAM could be efficiently adsorbed to any cation exchanger. Even then it was critical to adjust the pH and ionic strength of the applied specimens. Serial chromatography on two sulfonate-based cation-exchange resins proved effective. On the first of these (Fast Flow Sepharose-S; Pharmacia-LKB), washing and frontal elution effected separation of a large unabsorbed fraction from a single absorbance peak of basic proteins (not shown) that was collected in its entirety. Figure 1 illustrates the resolution afforded by gradient elution of the second cation exchanger (Mono S; Pharmacia-LKB); in this case, fractions 6 to 8 of preparation 1 were pooled and immediately carried on to the final chromatography. In other runs, this approach sometimes failed when, for unknown reasons, the absorbance profiles of consecutive and supposedly identical preparations were slightly different. Since Mono S fractions were stable at -70°C, most purifications were conducted using fractions that exhibited the highest mitogenic activity by biological assay. These fractions were then run individually over the final column. Active Mono S fractions typically contained -<10% pure MAM.
The last chromatographic step, hydrophobic interaction on alkyl-Superose (Pharmacia-LKB), removed unabsorbed proteins in the wash (not shown) and reliably gave elution profiles such as shown in Fig. 2 , where a complex of contaminant proteins was followed ultimately by a small, discrete absorbance band (fractions 13 and 14) corresponding to about 1 ml of 50 mM potassium phosphate with roughly 1.4 M (NH4)2SO4 (pH 7.2) and containing MAM that proved to be homogeneous. tion, a typical product of 20 ,ug of homogeneous MAM and about 20% overall yield corresponded to a mean yield of 80% per fractionating step.
The final peak fractions of all three preparations showed specific activities that varied in proportion to the mitogenic activities of the starting materials (1 X 102 to 7 x 102 U/mg) and ranged to about 1 x 108 to 10 X 108 U/mg of homogeneous MAM. Lability of MAM and variability in bioassays presumably each contributed variance to the specific activity results. Furthermore, interruptions during the purification scheme markedly reduced these yields, sometimes in excess of an order of magnitude.
Fractions corresponding to the peak that contained maximum MAM activity after alkyl-Superose chromatography were run in denaturing SDS-polyacrylamide gels (Fig. 3) . Single bands that corresponded to a molecular weight of approximately 27,000, as estimated by comparison with standard markers, were obtained.
Unlike Mono S fractions, alkyl-Superose fractions containing (NH4)2SO4 lost activity upon freezing. Furthermore, desalting the fractions against PBS or water by using dialysis or centrifugal ultrafiltration resulted in loss of all activity. Homogeneous MAM was found to be destroyed by exposure to glass and was also lost by absorption or denaturation on chargeneutral plastics, especially polystyrene. Homogeneous active peptide. Automated Edman degradation was conducted on fractions 13 and 14, which corresponded to the leading and trailing regions, respectively, of the MAM peak of preparation 1 (Fig. 2) . The first 53 of 54 residues of the N-terminal region of MAM were successfully sequenced ( Table 2 ). Material from On the basis of the N-terminal sequence, we synthesized three peptides which corresponded to MAM residues 1 to 13 (peptide 1), 27 to 44 (peptide 2), and 15 to 31 (MAM15-31; peptide 3), each with an added cysteine (designated by -C) ( Table 2) . None of the peptides tested were mitogenic for BALB/c splenocytes, nor were they inhibitory to concanavalin A (ConA)-mediated lymphocyte proliferation. However, peptide 3 at concentrations ranging from 0.1 to 2 mg/ml blocked proliferation of lymphocytes induced by the intact MAM molecule (Fig. 4) (2), we found that unusually high ionic strength in Sephadex G-50 gel filtration yielded a MAM-containing fraction that could successfully be further fractionated by cation-exchange chromatography. The high ionic strength would suppress ionic interaction or binding of MAM to other macromolecules but would enhance hydrophobic interactions. We also empirically determined that 30-kDa carbonic anhydrase defined the elution volumes of MAM in this gel filtration system. It should be noted that our gel filtration methods are specific for MAM and may give difficulties with other proteins.
The homogeneity of MAM prepared in the manner described above was indicated by a single band present on SDS-polyacrylamide gels of the MAM-containing peak resulting from alkyl-Superose chromatography. Further evidence of homogeneity was obtained by sequence analysis. Edman degradation (15) was used to obtain the N-terminal sequence of the leading and trailing portions of the active alkyl-Superose peak. In both cases, an identical sequence of the first 53 of 54 amino acids was obtained, thus confirming homogeneity. Fur- thermore, one of three synthesized peptides based upon this sequence (MAM15-31-C) was shown to block the mitogenic activity of the entire MAM molecule. These results further suggest that the derived sequence was in fact that of MAM. In a preliminary search of databases containing over 50,000 protein sequences, including those of the bacterial and retroviral superantigens, we failed to find any that contained regions structurally similar to the N-terminal amino acid sequence of MAM. Thus, MAM appears to represent a previously undescribed mitogenic protein.
The peptide blocking data suggest that the N-terminal region of MAM contains a biologically active region. Thus, the inhibition of MAM-induced proliferation by the peptide MAM15-31-C appeared to be specific for MAM, since no effects were seen on proliferation induced by ConA. Furthermore, the inhibition was not due to a toxic effect, since splenocytes treated with MAM15_31-C still responded normally to ConA. Relatively high concentrations of peptide were required to block even low doses of MAM, as has also been shown for other superantigens (19) . These observations might suggest a poor avidity of linear peptides for MHC or TCR molecules in comparison with motifs based upon the threedimensional superantigen structure.
Homogeneous MAM was found to possess the properties previously reported for impure preparations. Thus, the use of inbred and congenic mouse strains showed that MAM reacted preferentially with lymphocytes from strains that expressed Ea. Also, lymphocytes from mouse strains which lack most of the MAM-reactive Vs chains of the TCR gave poor responses to MAM. In addition, using T-cell hybridomas, we demonstrated that activation was dependent upon accessory cells and that the pattern of MAM-reactive V3 chains was the same for homogeneous and impure MAM.
Homogeneous MAM was also shown to have marked immunomodulatory responses in vivo. The suppressive effect on lymphocyte proliferation appeared to be V3 specific, since responses to MAM and SEB, which share usage of the V,38 TCR family, were both suppressed, whereas responses to SEA, which does not share V, TCR usage with MAM, were unaltered. Previous studies established that the apparent suppression induced by MAM was not due to a deletion or anergy of MAM-reactive clones, since CD4+ splenocytes from MAMinjected mice actively suppressed the response of splenocytes from control mice to MAM (13) .
Pure MAM in vivo also induced a marked increase in responses to bacterial LPS, thus confirming previous findings on more crude preparations in which activation of B-cell functions was found (5) . This is an important observation since it demonstrates that the superantigen bridge which cross links TH cells with resting B cells, leading to B-cell differentiation (36) , is also mediated by MAM and not by a different contaminating protein.
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Although the estimate of the concentration of homogeneous MAM used was only approximate, it is clear that MAM is much more active for H2-E-bearing murine lymphocytes than is SEA or SEB. Thus, whereas optimal concentrations of the staphylococcal superantigens are 5 to 10 ,ug/ml for BALB/c splenocytes (3, 4a, 16) , the optimal concentration of MAM for these cells was found to be approximately 5 ng/ml (Table 3) , i.e., 1,000-fold less. The differences in the degree of proliferation seen with mycoplasma or staphylococcal superantigens could reflect differences in the avidity of these proteins for murine MHC molecules or in the transduction of signals across the T-cell membrane by superantigen-MHC complexes. Human lymphocytes also differ in the degree of response to various superantigens. In this case, the staphylococcal superantigens are more potent in inducing proliferation of human T cells than is MAM (14, 16) .
The availability of homogeneous MAM is now allowing sequence and structural studies to be undertaken. Future work will compare the structure of MAM with that of other superantigens and will determine the molecular basis for the interaction of MAM with MHC and TCR molecules.
